Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Stifel
Deal Size : $30.0 million
Deal Type : Public Offering
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
Details : Precigen intends to use the net proceeds from the offering for advancing PRGN-2012 to regulatory approval for the treatment of Recurrent Respiratory Papillomatosis.
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Stifel
Deal Size : $30.0 million
Deal Type : Public Offering
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Precigen Reports Positive PRGN-2012 Data For Recurrent Respiratory Papillomatosis
Details : PRGN-2012 a new molecular entity, a HPV 6/11-specific T-cell response inducer, is an off the shelf OTS AdenoVerse gene therapy vaccine. It is in Phase I/II for recurrent respiratory papillomatosis.
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 03, 2024
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Precigen Gets Orphan Drug Designation for PRGN-2012 in Respiratory Papillomatosis
Details : PRGN-2012, a therapeutic vaccine using gorilla adenovector technology, is in phase 1/2 clinical trials for treating recurrent respiratory papillomatosis.
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 16, 2024
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), which is investigated for the treatment of recurrent respiratory papillomatosis.
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 09, 2023
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), which is investigated for the treatment of recurrent respiratory papillomatosis.
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
June 20, 2023
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRGN-2009,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-2009 leverages Precigen’s UltraVector® and AdenoVerse™ platforms and is an off-the-shelf adenoVerse immunotherapy in combination with pembrolizumab being developed to treat patients with recurrent or metastatic cervical cancer.
Brand Name : PRGN-2009
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 31, 2023
Lead Product(s) : PRGN-2009,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Autologous CAR-T Cell-based Therapy,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Alaunos Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Precigen regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform. Precigen will utilize the UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T t...
Brand Name : PRGN-3007
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Autologous CAR-T Cell-based Therapy,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Alaunos Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PRGN-3007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-3007 is the next generation of UltraCAR-T incorporating PD-1 inhibition, it simultaneously express a chimeric antigen receptor (CAR) targeting ROR1, mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene. expression.
Brand Name : PRGN-3007
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 29, 2023
Lead Product(s) : PRGN-3007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), to elicit immune responses directed against cells infected with human papillomavirus typ...
Brand Name : PRGN-2012
Molecule Type : Vaccine
Upfront Cash : Not Applicable
January 04, 2023
Lead Product(s) : PRGN-2012
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence.
Brand Name : PRGN-3006
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 12, 2022
LOOKING FOR A SUPPLIER?